| pubmed-article:12057651 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12057651 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:12057651 | lifeskim:mentions | umls-concept:C0014442 | lld:lifeskim |
| pubmed-article:12057651 | lifeskim:mentions | umls-concept:C0033262 | lld:lifeskim |
| pubmed-article:12057651 | lifeskim:mentions | umls-concept:C0006948 | lld:lifeskim |
| pubmed-article:12057651 | lifeskim:mentions | umls-concept:C0041942 | lld:lifeskim |
| pubmed-article:12057651 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:12057651 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:12057651 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:12057651 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:12057651 | pubmed:dateCreated | 2002-6-11 | lld:pubmed |
| pubmed-article:12057651 | pubmed:abstractText | The suitability of 4-di(2-chloroethyl)aminoanilino-4-hydroxyphenethylaminomethanone 2 to act as a prodrug for melanocyte-directed enzyme prodrug therapy (MDEPT) is assessed. Thus its synthesis, ability to generate a cytotoxic agent upon exposure to tyrosinase, and stability within different sera are reported. A comparison is made to illustrate that the new urea prodrug 2 is a more suitable candidate for MDEPT than the corresponding carbamate prodrug 1. | lld:pubmed |
| pubmed-article:12057651 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12057651 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12057651 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12057651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12057651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12057651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12057651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12057651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12057651 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12057651 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:12057651 | pubmed:issn | 0968-0896 | lld:pubmed |
| pubmed-article:12057651 | pubmed:author | pubmed-author:JordanAllan... | lld:pubmed |
| pubmed-article:12057651 | pubmed:author | pubmed-author:KhanTariq HTH | lld:pubmed |
| pubmed-article:12057651 | pubmed:author | pubmed-author:MalkinHughH | lld:pubmed |
| pubmed-article:12057651 | pubmed:author | pubmed-author:OsbornHelen... | lld:pubmed |
| pubmed-article:12057651 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12057651 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:12057651 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12057651 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12057651 | pubmed:pagination | 2625-33 | lld:pubmed |
| pubmed-article:12057651 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12057651 | pubmed:meshHeading | pubmed-meshheading:12057651... | lld:pubmed |
| pubmed-article:12057651 | pubmed:meshHeading | pubmed-meshheading:12057651... | lld:pubmed |
| pubmed-article:12057651 | pubmed:meshHeading | pubmed-meshheading:12057651... | lld:pubmed |
| pubmed-article:12057651 | pubmed:meshHeading | pubmed-meshheading:12057651... | lld:pubmed |
| pubmed-article:12057651 | pubmed:meshHeading | pubmed-meshheading:12057651... | lld:pubmed |
| pubmed-article:12057651 | pubmed:meshHeading | pubmed-meshheading:12057651... | lld:pubmed |
| pubmed-article:12057651 | pubmed:meshHeading | pubmed-meshheading:12057651... | lld:pubmed |
| pubmed-article:12057651 | pubmed:meshHeading | pubmed-meshheading:12057651... | lld:pubmed |
| pubmed-article:12057651 | pubmed:meshHeading | pubmed-meshheading:12057651... | lld:pubmed |
| pubmed-article:12057651 | pubmed:meshHeading | pubmed-meshheading:12057651... | lld:pubmed |
| pubmed-article:12057651 | pubmed:meshHeading | pubmed-meshheading:12057651... | lld:pubmed |
| pubmed-article:12057651 | pubmed:meshHeading | pubmed-meshheading:12057651... | lld:pubmed |
| pubmed-article:12057651 | pubmed:meshHeading | pubmed-meshheading:12057651... | lld:pubmed |
| pubmed-article:12057651 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12057651 | pubmed:articleTitle | Synthesis and analysis of urea and carbamate prodrugs as candidates for melanocyte-directed enzyme prodrug therapy (MDEPT). | lld:pubmed |
| pubmed-article:12057651 | pubmed:affiliation | Department of Chemistry, University of Reading, Whiteknights, Reading RG6 6AD, UK. | lld:pubmed |
| pubmed-article:12057651 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12057651 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
